All You Need to Know About Bio-Path Rating Upgrade to Buy
BPTH Stock | USD 0.74 0.03 3.90% |
Under 54% of Bio Path's traders are presently thinking to get in. The analysis of the overall investor sentiment regarding Bio Path Holdings suggests that some traders are interested. Bio Path's investing sentiment shows overall attitude of investors towards Bio Path Holdings.
Bio |
Bio-Path has been upgraded to a Zacks Rank 2 , reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Read at zacks.com
Bio Path Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Bio Path can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
ACHR, BPTH, PLUG, REGRF:
recently @ finance.yahoo.com
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bio Path Fundamental Analysis
We analyze Bio Path's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Path using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Path based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Bio Path is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Bio Path Holdings Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bio Path stock to make a market-neutral strategy. Peer analysis of Bio Path could also be used in its relative valuation, which is a method of valuing Bio Path by comparing valuation metrics with similar companies.
Peers
Bio Path Related Equities
AKTX | Akari Therapeutics | 12.40 | ||||
CAPR | Capricor Therapeutics | 3.31 | ||||
CRNX | Crinetics Pharmaceuticals | 0.33 | ||||
ALRN | Aileron Therapeutics | 0.35 | ||||
ACHV | Achieve Life | 0.68 | ||||
NXTC | NextCure | 0.85 | ||||
MBRX | Moleculin Biotech | 2.89 | ||||
BNTC | Benitec Biopharma | 3.27 | ||||
PULM | Pulmatrix | 4.52 |
Complementary Tools for Bio Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |